(8CI)-1-(2-苯并噻唑)-3-乙基脲 | 15382-15-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: (8CI)-1-(2-苯并噻唑)-3-乙基脲
• 英文名称: 1-(benzo[d]thiazol-2-yl)-3-ethylurea
• 英文别名: 1-(benzo[d]thiazole-2-yl)-3-ethylurea；1-(1,3-Benzothiazol-2-yl)-3-ethylurea
• CAS: 15382-15-7
• 化学式: C₁₀H₁₁N₃OS
• mdl: MFCD00247564
• 分子量: 221.283
• InChiKey: XITQIIBGCRJHAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  82.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氨基苯并噻唑 、 异氰酸乙酯 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 以59%的产率得到(8CI)-1-(2-苯并噻唑)-3-乙基脲
  参考文献：
  名称：

  Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents

  摘要：

  Our strategy to combat resistant bacteria consisted of targeting the GyrB/ParE ATP-binding sites located on bacterial DNA gyrase and topoisomerase IV and not utilized by marketed antibiotics. Screening around the minimal ethyl urea binding motif led to the identification of isoquinoline ethyl urea 13 as a promising starting point for fragment evolution. The optimization was guided by structure-based design and focused on antibacterial activity in vitro and in vivo, culminating in the discovery of unprecedented substituents able to interact with conserved residues within the ATP-binding site. A detailed characterization of the lead compound highlighted the potential for treatment of the problematic fluoroquinolone-resistant MRSA, VRE, and S. pneumoniae, and the possibility to offer patients an intravenous-to-oral switch therapy was supported by the identification of a suitable prodrug concept. Eventually, hERG K-channel block was identified as the main limitation of this chemical series, and efforts toward its minimization are reported.

  DOI：

  10.1021/acs.jmedchem.6b01834

文献信息

• BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME
  申请人：Hahn Hoh-Gyu

  公开号：US20110319456A1

  公开（公告）日：2011-12-29

  Novel benzoarylureido compounds and a use thereof for prevention and/or treatment of the neurodegenerative brain disease are provided. The neurodegenerative brain diseases may include Alzheimer's disease, dementia, Parkinson's disease, stroke, amyloidosis, Pick's disease, Lou Gehrig's disease, Huntington's disease, Creutzfeld-Jakob disease, and the like.

  提供了新型苯甲酰脲类化合物及其用于预防和/或治疗神经退行性脑疾病的用途。神经退行性脑疾病可能包括阿尔茨海默病、痴呆症、帕金森病、中风、淀粉样变性、皮克氏病、路易·格希病、亨廷顿病、克罗伊茨菲尔德-雅各布病等。
• [EN] BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS<br/>[FR] BENZOTHIAZOLES ET LEURS ANALOGUES AZA UTILISÉS COMME AGENTS ANTIBACTÉRIENS
  申请人：RANBAXY LAB LTD

  公开号：WO2009156966A1

  公开（公告）日：2009-12-30

  The present invention provides Gyrase B and/or Topoisomerase IV par E inhibitors, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed by gram positive, gram negative and anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Pseudomonas spp., Acenetobacter spp., Moraxalla spp., Chlamydia spp., Mycoplasma spp., Legionella spp., Ktycobacterium spp., Helicobacter, Clostridium spp., Bacteroides spp., Coryne bacterium, Bacillus spp., Enterobactericeae,' (E.coli, Klebsiella spp., Proteus spp.,etc. ) or any combination thereof Also provided, are processes for preparing compounds disclosed herein, pharmaceutical compositions containing compounds disclosed herein, and methods of treating bacterial infections. (Formula)

  本发明提供了Gyrase B和/或Topoisomerase IV par E抑制剂，可用作抗菌剂。本文披露的化合物可用于治疗或预防由革兰氏阳性、革兰氏阴性和厌氧菌引起或促成的疾病，更具体地针对例如葡萄球菌、链球菌、肠球菌、流感嗜血杆菌、假单胞菌、阿氏耶森氏菌、摩拉氏菌、沙雷菌、支原体、支原体、军团菌、肺结核杆菌、幽门螺杆菌、梭菌、拮抗杆菌、克雷伯菌科（大肠杆菌、克雷伯菌等）、或其任意组合。还提供了制备本文披露的化合物的方法、含有本文披露的化合物的药物组合物，以及治疗细菌感染的方法。
• Facile preparation of fused ring azolylureas
  作者：Joseph E. Drumm、David D. Deininger、Arnaud LeTiran、Tiansheng Wang、Anne-Laure Grillot、Yusheng Liao、Steven M. Ronkin、Dean P. Stamos、Qing Tang、Shi-Kai Tian、Patricia Oliver-Shaffer

  DOI：10.1016/j.tetlet.2007.05.159

  日期：2007.7

  Two novel reagents for the preparation of fused ring azolylureas are presented. (C) 2007 Elsevier Ltd. All rights reserved.
• 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
  申请人：Abbott GmbH & Co. KG

  公开号：EP1254123A1

  公开（公告）日：2002-11-06
• BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS
  申请人：Ranbaxy Laboratories Limited

  公开号：EP2321309A1

  公开（公告）日：2011-05-18